Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4811-4817

  Wertel, I ^a   Surowka J ^a   Polak, G ^a   Barczynski B ^a   Bednarek, W ^a   Jakubowicz Gil, J ^b   Bojarska Junak, A ^a   Kotarski, J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

CCL22; Ovarian cancer; Peritoneal fluid; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE DERIVED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; CCL22 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CELL MIGRATION; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; ADOLESCENT; ASCITES FLUID; BIOSYNTHESIS; DENDRITIC CELL; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CHEMOKINE CCL22; DENDRITIC CELLS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84938973070     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3133-8     Document Type: Article

References (32)

1. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.
2. Wertel I, Nowicka A, Rogala E, Kotarski J. Peritoneal immune system in patients with advance epithelial ovarian cancer. Int Rev Immunol. 2011;30:87–101.
3. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009;69:3995–4000.
4. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72.
5. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–31.
6. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58:449–59.
7. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4:e6412. Erratum in: PLoS One. 2013;8(7).
8. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4 + CD25+ regulatory T cells. J Exp Med. 2001;194:847–53.
9. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69:2000–9.
10. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 2011;71:6143–52.
11. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med. 1997;185:1595–604.
12. Hashimoto S, Nakamura K, Oyama N, Kaneko F, Tsunemi Y, Saeki H, et al. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J Dermatol Sci. 2006;44:93–9.
13. Layseca-Espinosa E, Korniotis S, Montandon R, Gras C, Bouillié M, Gonzalez-Amaro R, et al. CCL22-producing CD8α − myeloid dendritic cells mediate regulatory T cell recruitment in response to G-CSF treatment. J Immunol. 2013;191:2266–72.
14. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). J Leukoc Biol. 2000;68:400–4.
15. Chantry D, Romagnani P, Raport CJ, Wood CL, Epp A, Romagnani S, et al. Macrophage-derived chemokine is localized to thymic medullary epithelial cells and is a chemoattractant for CD3(+), CD4(+), CD8(low) thymocytes. Blood. 1999;94:1890–8.
16. Li YQ, Liu FF, Zhang XM, Guo XJ, Ren MJ, Fu L. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer. PLoS One. 2013;4(8):e76379.
17. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, et al. CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398–405.
18. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008;122:2286–93.
19. Maruyama T, Kono K, Izawa S, Mizukami Y, Kawaguchi Y, Mimura K, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:422–9.
20. Yanai M, Sato K, Aoki N, Takiyama Y, Oikawa K, Kobayashi H, et al. The role of CCL22/macrophage-derived chemokine in allergic rhinitis. Clin Immunol. 2007;125:291–8.
21. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol. 2008;19:605–13.
22. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008;140:527–36.
23. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood. 2011;118:4853–62.
24. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
25. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7–15.
26. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006;177:84–91.
27. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J. Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom. 2008;74:251–8.
28. Goyne HE, Stone PJ, Burnett AF, Cannon MJ. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 2014;37:163–9.
29. Li X, Ye DF, Xie X, Chen HZ, Lu WG. Proportion of CD4 + CD25+ regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest. 2005;23:399–403.
30. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD4 + CD25− T cells into CD4 + CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007;178:2883–92.
31. Li X, Ye F, Chen H, Lu W, Wan X, Xie X. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett. 2007;253:144–53.
32. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.